Heparin-Free DALI LDL-Apheresis in Hyperlipidemic Patients: Efficacy,Safety and Biocompatibility

Abstract

Background and Aim of Study

In routine DALI apheresis - the first technique for direct adsorption of lipoproteins from whole blood - heparin plus citrate (ACD-A) is used as anticoagulation regimen. However, recently several publications have warned of heparin-induced thrombocytopenia as a rare but potentially life-threatening complication of heparin administration (HIT type 2). The aim of the present study was therefore to test the efficacy and biocompatibility of DALI using a heparin-free anticoagulation regimen consisting exclusively of citrate.

Methods

Four symptomatic hypercholesterolemic patients on regular DALI apheresis were switched to the heparin-free protocol for two sessions each. Two of the patients were on oral anticoagulation using phenprocoumon. In the weekly sessions, 1.3 patient blood volumes were processed at a blood flow rate of 60 ml/min using ACD-A at a ratio of 1:20 (v/v) during adsorber priming and the session.

Results

Clinically, all sessions were essentially uneventful. Uncorrected lipoprotein reductions amounted to 65% for LDL-C, 62% for Lp(a), 53% for VLDL-C, 24% for HDL-C, 17% for triglycerides and 19% for fibrinogen. Cell counts remained virtually constant. No signs of hemolysis or clotting could be detected. Thromboplastin time (Quick) was slightly prolonged and partial thromboplastin time (PTT) moderately elevated in all patients. In constrast, whole blood coagulation time acc. to Lee-White and activated clotting times were increased only in orally anticoagulated patients. Biocompatibility in terms of complement, leukocyte and thrombocyte activation was excellent. Bradykinin activation was moderate peaking at 3038 pg/ml in the efferent line. Systemic thrombin-antithrombin complex (TAT) reflected perfect anticoagulation in orally anticoagulated patients and adequate anticoagulation in the patients without phenprocoumon.

Conclusion

In this pilot study, heparin-free DALI apheresis was safe and effective and may thus be performed in LDL-apheresis dependent patients who suffer from heparin intolerance.

Keywords

LDL-apheresis DALI Biocompatibility Citrate Heparin HIT

Get full access to this article

View all access options for this article.

References

Bosch

. Lipid apheresis: From a heroic treatment to routine clinical practice. Artif Organs 1996; 20(5): 414–9.

Gordon

B.R.

, Saal

S.D.

. Current status of LDL-apheresis for the theraphy of severe hyperlipidemia. Curr Opin Lipidol 1996; 7: 381–4.

Ballantyne

C.M.

, Herd

J.A.

, Dunn

J.K.

, Jones

P.H.

, Farmer

J.A.

, Gotto

A.M.

. Effects of lipid lowering theraphy on progression of coronary and carotid artery disease. Curr Opin Lipidol 1997; 8: 354–61.

Bosch

, Schmidt

, Blumenstein

, Gurland

H.J.

. Lipid apheresis by hemoperfusion: In vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Int J Artif Organs 1993; 17(7): 640–52.

Bosch

, Lennertz

, Schmidt

. DALI apheresis in hyperlipidemic patients: Biocompatibility, efficacy and selectivity of direct adsorption of lipoproteins from whole blood. Artif Organs 2000; 24(2): 81–90.

Bosch

, Schmidt

, Kleophas

. LDL hemoperfusion - a new procedure for LDL apheresis: First clinical application of an LDL adsorber compatible with human whole blood. Artif Organs 1997; 21(9): 997–82.

Hirsh

. Heparin. N Engl J Med 1991; 324: 1565–74.

Aster

. Heparin-induced thrombocytopenia and thrombosi. N Engl J Med 1995; 332: 1374–6.

Kleinschmidt

, Seyfert

U.T.

. Die Heparin-induzierte Thrombocytopenie (HIT). Anaesthesist 1999; 48: 771–85.

10.

Shimamoto

, Ando

, Tanaka

. An improved method for the determination of human blood kinin levels by sensitive kinin radioimmunoassay. Endokrinol Jpn 1982; 29: 487–94.

11.

Lindhout

. Biocompatibility of extracorporeal blood treatment. Selection of haemostatic parameters. Nephrol Dial Transplant 1994; 9(Suppl 2): S83–9.

12.

Dräger

L.J.

, Julius

, Kraenzle

. DALI-the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results. Eur J Clin Invest 1998; 28(12): 994–1002.

13.

Person

, Nordenstrom

, Nilsson-Ehle

, Hagenfeldt

. Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin. Eur J Clin Invest 1985; 15(4): 215–20.

14.

Yamamoto

, Kojima

, Shiba-Harada

, Kawaguchi

, Hatanaka

. Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose columns. Artif Organs 1992; 16: 177–81.

15.

Kazatchkine

M.D.

, Fearon

D.T.

, Metcalfe

D.D.

, Rosemberg

R.D.

, Austen

K.F.

. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981; 67: 223–8.

16.

Wegmüller

, Kazatchkine

M.D.

, Nydegger

U.E.

. Complement activation during extracorporeal blood bypass. Plasma Ther Transfus Technol 1983; 4: 361–71.

17.

Bhoola

K.D.

, Figueroa

C.D.

, Worthy

. Bioregulation of kinins: Kallikrein, kininogens and kininases. Pharmacol Rev 1992; 44: 1–67.

18.

Bosch

, Lennertz

, Schmidt

. Direct adsorption of lipoproteins from whole blood by DALI apheresis: Clinical efficacy and biocompatibility. Int J Artif Organs 1998; 21: 611.

19.

Bosch

, Lennertz

, Kordes

, Samtleben

. Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): Clinical experience from a single center. Ther Aphresis 1999, 3(3): 209–13.